🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Stanford neuro-oncologist Michelle Monje is pursuing a cure for a deadly pediatric brain cancer – and reshaping our understanding of how cancer and brain development intersect: stanford.io/3ZoFkWP

“Covariants in KRAS/STK11 or KRAS/KEAP1 were associated with lack of pCR. Patients with single-station or multistation N2/N3 disease exhibited comparable pathological outcomes.” jamanetwork.com/journals/jamao… Biagio Ricciuti, MD, PhD Dana-Farber's Lowe Center for Thoracic Oncology JAMA Oncology #lcam #lcsm

Congrats to Nazli Dizman for receiving a Conquer Cancer, the ASCO Foundation YIA! Well deserved and mentored by Dr. Jenn McQuade on microbiome and diet MD Anderson Cancer Center Sumanta K. Pal, MD, FASCO

One of my current international students at Harvard just filed two patents with me. These patented technologies are now being licensed by a small U.S. business, which will create jobs *across the country* and generate tax revenue for the U.S.

Honored to get Conquer Cancer, the ASCO Foundation ASCO CDA—a milestone I never imagined when I began this journey. Grateful to Conquer Cancer, the ASCO Foundation that believes in potential and novel high risk ideas! More thrilled to see other 🌟 Amin Nassar, MD Nazli Dizman YIA and Kaushal Parikh Misty Dawn Shields CDA!!

Very special to be awarded for Faculty Achievement in Basic Science at the Faculty Honors Convocation, along with colleagues who I deeply admire and the one and only Dr. Glaucomflecken MD Anderson Cancer Center #LCSM

It’s #ADCyear, and the good news keep coming! The ASCENT-03 phase 3 trial of SG vs chemo as 1L therapy for IO-ineligible mTNBC is announced to be positive, with significant PFS benefit. One more setting in which an ADC moves to first line. Exciting times! businesswire.com/news/home/2025…

📍Now it's time to highlight those abstracts that we'll see at #ASCO25 in kidney & bladder confirming their value as standard of care: 🏹1. #CHECKMATE-214: Among those patients who responded to Nivo-Ipi (42%) with 1L I/P prognosis, the possibilities to maintain the response

Paolo Tarantino, MD, PhD, (Paolo Tarantino) discusses potentially practice-changing #BreastCancer research that will be presented at the #ASCO25 Annual Meeting. onclive.com/view/dr-tarant… OncLive.com

We are excited to welcome, Daphna Spiegel, MD, MS to the BOC! Dr. Spiegel is a Radiation Oncologist with professional interests in patient-centered care, multidisciplinary collaboration, and research to reduce treatment-related toxicities and improve survivorship outcomes. ‌She

Digital breast tomosynthesis improves specificity and reduces recall and advanced cancer rates compared to digital mammography in women with a family history of breast cancer. ja.ma/4mpAMtr

Scientists have found that the #circadian clock gene per2 boosts daytime antibacterial activity in #neutrophils by promoting infection-responsive hmgb1a expression in larval zebrafish. University of Auckland | Waipapa Taumata Rau Learn more in Science #Immunology: scim.ag/43GpWHU

ASCENT-03 & -04 are positive: we may soon have the option of 1L SG (+/- pembro) for mTNBC. If TB02 is positive, we may also soon have Dato-DXd. ❓How will you treat a 50yo patient with TNBC (PD-L1-, IHC 1+) de novo metastatic to the lungs after progression on 1L SG (PFS 9 mo)?

Rare cancer think tank. Save the date. ⁦TargetCancer Fdn⁩ with special focus on cholangiocarcinoma

I discuss the urgent crisis from the loss of federal support of science in the US and recent clinical gene editing breakthroughs with Walter Isaacson & Christiane Amanpour on Amanpour and Company, airing on PBS tonight at 11 pm ET, and on CNN International earlier today. Pls share! youtube.com/watch?v=8YhJM6…

I gotta debate against Jessica Lin and I am not ready

Cancer Surveillance in the United States in Jeopardy: Leveraging 21st Century Technology to Enhance Public Health. ascopubs.org/doi/full/10.12… ASCO American Cancer Society Journal of Clinical Oncology JCO Oncology Practice #CancerResearch #CancerCare #Healthcare #MedTech Robin Yabroff

The good news: we’ll soon have more ADCs in earlier indications. The bad news: we have no biomarkers to guide their use. At Dana-Farber’s Breast Oncology Center we’re committed to fill this gap. At #ASCO25 we’ll present a pilot study with HER2DX & RPPA. Join us at the poster! meetings.asco.org/abstracts-pres…

The evolving role of immunotherapy in early-stage lung cancer will be a hot topic at #ASCO25 Don’t miss these sessions! tinyurl.com/498bfrsv Penn Medicine MD Penn Medicine Penn Medicine - Abramson Cancer Center ASCO OncoAlert Oncology Brothers

For a patient with mTNBC treated with first line SG, most would give T-DXd in immediate sequence. Worth highlighting this Flatiron analysis we presented at #ASCO24 (now in press), finding worse outcomes with T-DXd for mTNBC if previously exposed to SG.